# Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)

Study · id `cardio:ct-nct07252544` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07252544](<https://clinicaltrials.gov/study/NCT07252544>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07252544

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3156 participants.

## Technical summary

Registry record NCT07252544. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-01 (anticipated); primary completion 2027-08-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 3156 participants (planned count; ClinicalTrials.gov record NCT07252544, source copy `cardio:ctgov-nct07252544-2025-11-26`, retrieved 2026-10-26)
- Planned start: 2025-12-01 (anticipated) (ClinicalTrials.gov record NCT07252544, source copy `cardio:ctgov-nct07252544-2025-11-26`, retrieved 2026-10-26)
- Primary completion: 2027-08-31 (anticipated) (ClinicalTrials.gov record NCT07252544, source copy `cardio:ctgov-nct07252544-2025-11-26`, retrieved 2026-10-26)
- Completion: 2028-02-29 (anticipated) (ClinicalTrials.gov record NCT07252544, source copy `cardio:ctgov-nct07252544-2025-11-26`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07252544-2025-11-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)
- Condition: Stroke, Lacunar
- Condition: Stroke, Acute Ischemic
- Condition: Cerebral Small Vessel Diseases
- Intervention (Drug): Isosorbide Mononitrate
- Intervention (Drug): Butylphthalide
- Intervention (Drug): Isosorbide Mononitrate Placebo
- Intervention (Drug): Butylphthalide Placebo
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER
- Collaborator: Shenzhen Second People's Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Cerebral small vessel disease (`cardio:cerebral-small-vessel-disease`)
- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)
- Registry lists this organization as a collaborator: Shenzhen Second People's Hospital (`cardio:org-shenzhen-second-people-s-hospital`)

## Provenance

Content hash: 95d06380a885826c526f8ea2c155c16bfb35345ab81397822df8cb6bedba9ff8
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
